CA2879249A1 - 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel - Google Patents

3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel Download PDF

Info

Publication number
CA2879249A1
CA2879249A1 CA2879249A CA2879249A CA2879249A1 CA 2879249 A1 CA2879249 A1 CA 2879249A1 CA 2879249 A CA2879249 A CA 2879249A CA 2879249 A CA2879249 A CA 2879249A CA 2879249 A1 CA2879249 A1 CA 2879249A1
Authority
CA
Canada
Prior art keywords
phenyl
compound according
fluoro
alkyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2879249A
Other languages
English (en)
French (fr)
Inventor
Luke Green
Haiyan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2879249A1 publication Critical patent/CA2879249A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2879249A 2012-10-29 2013-10-25 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel Abandoned CA2879249A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12190319 2012-10-29
EP12190319.9 2012-10-29
PCT/EP2013/072361 WO2014067861A1 (en) 2012-10-29 2013-10-25 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel

Publications (1)

Publication Number Publication Date
CA2879249A1 true CA2879249A1 (en) 2014-05-08

Family

ID=47143594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2879249A Abandoned CA2879249A1 (en) 2012-10-29 2013-10-25 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel

Country Status (23)

Country Link
US (1) US9611232B2 (enExample)
EP (1) EP2912034B1 (enExample)
JP (1) JP6216385B2 (enExample)
KR (1) KR20150075091A (enExample)
CN (1) CN104781256B (enExample)
AR (1) AR093168A1 (enExample)
AU (1) AU2013339607A1 (enExample)
BR (1) BR112015003996A2 (enExample)
CA (1) CA2879249A1 (enExample)
CL (1) CL2015000906A1 (enExample)
CO (1) CO7170170A2 (enExample)
CR (1) CR20150159A (enExample)
EA (1) EA026161B1 (enExample)
IL (1) IL237331A0 (enExample)
IN (1) IN2015DN00961A (enExample)
MA (1) MA38135B1 (enExample)
MX (1) MX2015002399A (enExample)
PE (1) PE20150775A1 (enExample)
PH (1) PH12015500292A1 (enExample)
SG (1) SG11201500585XA (enExample)
TW (1) TW201422596A (enExample)
UA (1) UA114649C2 (enExample)
WO (1) WO2014067861A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102047502B1 (ko) * 2016-06-20 2019-11-22 셀라이온바이오메드 주식회사 포타슘 채널 단백질을 이용한 암 진단용 조성물
KR102865950B1 (ko) 2019-03-22 2025-09-30 사니오나 에이/에스 신규의 칼륨 채널 억제제
AU2021350333A1 (en) 2020-09-22 2023-05-04 Saniona A/S Novel potassium channel inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538424C2 (de) * 1975-08-29 1983-01-05 Nordmark-Werke Gmbh, 2000 Hamburg 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat
ES2000907A6 (es) * 1985-09-09 1988-03-16 Otsuka Pharma Co Ltd Procedimiento de preparar compuestos 2-oxaisocefen microbiologicamente activos
KR930703262A (ko) * 1990-11-06 1993-11-29 스튜어트 알. 슈터 이미다졸리디논 화합물
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1997031892A1 (fr) * 1996-03-01 1997-09-04 Sankyo Company, Limited Derives d'acide hydroxamique
EP1144387A1 (en) * 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
JP3966693B2 (ja) * 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
IL150651A0 (en) * 2000-01-20 2003-02-12 Eisai Co Ltd Nitrogen-containing cyclic compound and pharmaceutical compositions containing the same
AU2002221827A1 (en) * 2000-11-22 2002-06-03 Bayer Aktiengesellschaft Novel lactame-substituted pyrazolopyridine derivatives
EP1781635B1 (en) 2004-07-29 2012-06-13 Merck Sharp & Dohme Corp. Potassium channel inhibitors
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds
US20100056637A1 (en) 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2007109098A2 (en) * 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
TW201026708A (en) 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2010123997A1 (en) * 2009-04-22 2010-10-28 Achaogen, Inc. Carbacephem beta-lactam antibiotics

Also Published As

Publication number Publication date
KR20150075091A (ko) 2015-07-02
EP2912034B1 (en) 2017-05-31
CL2015000906A1 (es) 2015-09-11
TW201422596A (zh) 2014-06-16
MA38135A2 (fr) 2016-11-30
EP2912034A1 (en) 2015-09-02
SG11201500585XA (en) 2015-04-29
AR093168A1 (es) 2015-05-20
US20150246894A1 (en) 2015-09-03
JP2015535231A (ja) 2015-12-10
IL237331A0 (en) 2015-04-30
PE20150775A1 (es) 2015-05-21
HK1207632A1 (en) 2016-02-05
US9611232B2 (en) 2017-04-04
PH12015500292A1 (en) 2015-04-20
EA201590729A1 (ru) 2015-07-30
MX2015002399A (es) 2015-06-10
JP6216385B2 (ja) 2017-10-18
CR20150159A (es) 2015-04-30
AU2013339607A1 (en) 2015-02-05
UA114649C2 (uk) 2017-07-10
EA026161B1 (ru) 2017-03-31
IN2015DN00961A (enExample) 2015-06-12
CN104781256A (zh) 2015-07-15
WO2014067861A1 (en) 2014-05-08
CO7170170A2 (es) 2015-01-28
MA38135B1 (fr) 2018-11-30
CN104781256B (zh) 2017-09-29
BR112015003996A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
JP7090770B2 (ja) Ｅｐ４アンタゴニスト
US20110230493A1 (en) 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
WO2018049068A1 (en) N-acyl amino acid compounds and methods of use
EP1432700A1 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents
US20100113465A1 (en) 7-azaspiro[3.5]nonane-7-carboxamide compounds
KR20130143138A (ko) 관절염 치료에 유용한 신규 이미다졸 유도체
US11724997B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
EP4364798A2 (en) Compounds and compositions for treating conditions associated with apj receptor activity
JP2006510728A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
CN104245696A (zh) 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
AU2016353348A1 (en) Heterocyclic compounds for the treatment of disease
US9611232B2 (en) Oxazolidinone and imidazolidinone compounds
KR100401314B1 (ko) 벤즈이미다졸 유도체 및 그의 약학적으로 허용되는 염
CN119403794A (zh) 用于治疗trpm3介导的病症的新型衍生物
JPWO1999024425A1 (ja) ベンズイミダゾール誘導体及びその薬学的に許容される塩
JP2020506168A (ja) 新規ＪＡＫキナーゼ阻害剤としての５−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−５−アザスピロ［２．５］オクタン−８−カルボン酸誘導体
JP2021500416A (ja) 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
KR102640385B1 (ko) 고혈압 및/또는 폐 섬유증 치료용 조성물
HK1207632B (en) 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
WO2019179362A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
HK40111351A (en) Compounds and compositions for treating conditions associated with apj receptor activity
AU2002334771A1 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181025